Diazyme Goes Green: Transitioning to a Paperless Future with TechDocs
26th Aug 2024
In our ongoing commitment to sustainability, Diazyme Laboratories is taking major steps towards reducing our environmental footprint by going green! One of the key initiatives in this effort is the transition to a paperless system for our product documentation.Simplified Access to Important DocumentsTo achieve this, we’ve launched TechDocs—a new platform that allows users to access and downlo
…
Event Recap: Conference Kick Off with Kappa and Lambda - ADLM 2024
15th Aug 2024
At this year's ADLM Lab Expo, Diazyme proudly hosted its first-ever industry workshop, marking a significant milestone for the company. The Diazyme Kappa & Lambda Free Light Chain Key Opinion Leader (KOL) event took place on Tuesday, July 30th, 2024, at the McCormick Place Convention Center. This educational session, titled “Conference Kick-off with Kappa and Lambda: An In-Depth Workshop on
…
Carolina Liquid Chemistries Corp. and Diazyme Laboratories Announce Partnership
2nd Feb 2023
Carolina Liquid Chemistries Corp. and Diazyme Laboratories, Inc. Announce Partnership Expanding Test Menu on the Diazyme DZ-Lite™ c270 Benchtop Clinical Chemistry Analyzer, Adding 25 New Assays On Top of Over 50 CLIA Categorized Assays
GREENSBORO, NC — (Jan. 20, 2023) – Carolina Liquid Chemistries Corp. (CLC) and Diazyme Laboratories, Inc. (Diazyme) announce a partnership to expan
…
Diazyme Laboratories, Inc. Receives Second FDA EUA for COVID-19 Antibody Test
17th Aug 2020
SAN DIEGO, CA - (August 17, 2020) Diazyme announces receiving FDA Emergency Use Authorization (EUA) letter for the Diazyme DZ-Lite SARS-CoV-2 IgM CLIA test. The Diazyme IgM test runs on the fully automated DZ-Lite 3000 Plus chemiluminescence analyzer.
"Diazyme continues to serve during the public health emergency with innovative products in COVID-19 serology (antibody) testing. The IgM test is t
…
Why D-Dimer test is Important in Severe COVID-19 Infection
3rd Aug 2020
SAN DIEGO, CA
Severe COVID-19 infection is associated with high morbidity and mortality with 50% of the deaths determined to be due to coagulopathy1. Studies have revealed that patients with serious infection are more likely to have COVID-19 associated coagulopathy than patients with mild infection, and those who die from COVID-19 are more likely to have met the International Society on Thrombos
…